64586-20-5

Upstream product

• 2077-19-2 2-(4-bromophenyl)propan-2-ol 
• 32454-35-6 2-(4-bromophenyl)-2-methylpropionic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1173047-86-3 2-(4-bromophenyl)propan-2-amine hydrochloride 
• 64586-24-9 N-(p-Brom-α,α-dimethylbenzyl)formamid 
• 75-44-5 phosgene 
• 17797-12-5 1-(4-bromophenyl)-1-methylethylamine 

Downstream Products

• 64797-85-9 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1,1-dipropyl-urea 
• 64797-81-5 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1-ethyl-1-phenyl-urea 
• 64797-52-0 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-isopropyl-urea 
• 64797-99-5 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-butyl-urea 
• 64797-53-1 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-phenyl-urea 
• 64797-88-2 1-Benzyl-3-[1-(4-bromo-phenyl)-1-methyl-ethyl]-1-methyl-urea 
• 64797-56-4 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-p-tolyl-urea 
• 64797-55-3 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-(3,5-dichloro-phenyl)-urea 
• 64797-79-1 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1-methyl-1-phenyl-urea 
• 64797-84-8 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1,1-diethyl-urea 
• 64797-83-7 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1,1-dimethyl-urea 
• 64797-97-3 1-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-3-ethyl-urea 
• 64797-80-4 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1-(3-chloro-phenyl)-1-methyl-urea 
• 64797-82-6 3-[1-(4-Bromo-phenyl)-1-methyl-ethyl]-1-butyl-1-phenyl-urea 

Relevant academic research and scientific papers

TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS)

This disclosure relates to a method of treating a ciliopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said method.

METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES

This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes pain, such as abdominal pain, and dermatological disorders, such as angiokeratoma, in a patient having a disease such as Fabry disease. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.

A Copper-Catalyzed Aerobic [1,3]-Nitrogen Shift through Nitrogen-Radical 4-exo-trig Cyclization

A novel radical [1,3]-nitrogen shift catalyzed by copper diacetate under an oxygen atmosphere (1 atm) has been developed for the construction of a diverse range of indole derivatives from α,α-disubstituted benzylamine. In this reaction, oxygen was used as a clean terminal oxidant, and water was produced as the only by-product. Five inert bonds were cleaved, and two C?N bonds and one C?C double bond were constructed in one pot during this transformation. This unique method demonstrated broad application protential for the late-stage modification of biologically active natural products and drugs. Mechanistic investigations indicate that a unique 4-exo-trig cyclization of an aminyl radical onto a phenyl ring is involved in the catalytic cycle.